A phase II study of sunitinib in advanced hepatocellular carcinoma

Barone, Carlo; Basso, Michele; Biolato, Marco; Pompili, Maurizio; Rufini, Vittoria; Miele, Luca; Basso, Maria Sole; Gaetano, Anna Maria De; Castaldi, Paola; Iaculli, Alessandro; Leccisotti, Lucia; Riccardi, Laura

doi:10.1016/j.dld.2013.01.002

Cited by 21 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib shows evidence of modest antitumor activity with manageable AEs in several clinical trials in patients with advanced HCC [24][25][26] . The futility and safety reasons of sunitinib forced a phase Ⅲ trial (NCT00699374) to stop, which compared sunitinib (37.5 mg/d) with sorafenib (400 mg bid) in patients with advanced HCC.…”

Section: Other Antiangiogenic Therapiesmentioning

confidence: 99%

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges

Deng

Zeng

Shen

2015

WJH

144

121

View full text Add to dashboard Cite

show abstract

Section: Other Antiangiogenic Therapiesmentioning

confidence: 99%

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges

Deng

Zeng

Shen

2015

WJH

144

121

View full text Add to dashboard Cite

show abstract

“…Moreover, the efficacy of sunitinib in patients with advanced HCC was evaluated in four phase II studies [26][27][28][29].…”

Section: Figurementioning

confidence: 99%

Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking

Eldehna

Farès

Ibrahim

et al. 2015

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

“…In multiple phase II clinical trials, advanced HCC patients were treated with sunitinib and was found to have an ORR of 2.7%–12% and median OS of 5.8–9.8 months [65,66,67,68]. In the phase II trials with high dose of sunitinib (50 mg daily for four weeks and no therapy for 2 weeks), it was noted to have a high incidence of toxicities with 80% of the patients having grade 3 or 4 toxicity such as thrombocytopenia, neutropenia, asthenia, and hand-foot syndrome [65,68]. The studies also noted about 10.8%–17.6% with fatal treatment-related toxicity [65,68].…”

Section: Molecularly Targeted Agentmentioning

confidence: 99%

“…In the phase II trials with high dose of sunitinib (50 mg daily for four weeks and no therapy for 2 weeks), it was noted to have a high incidence of toxicities with 80% of the patients having grade 3 or 4 toxicity such as thrombocytopenia, neutropenia, asthenia, and hand-foot syndrome [65,68]. The studies also noted about 10.8%–17.6% with fatal treatment-related toxicity [65,68]. In a large phase III trial comparing sunitinib at 37.5 mg daily for four out of every six weeks with sorafenib at 400 mg twice daily.…”

Section: Molecularly Targeted Agentmentioning

confidence: 99%

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy

2015

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer related mortality worldwide. The incidence of HCC has been increasing annually. Viral infection, alcohol usage, and other causes of cirrhosis have been identified as major risk factors for HCC development. The underlying pathogenesis has not been as well defined. There have been multiple hypotheses to the specific mechanisms of hepatocarcinogenesis and they share the common theme of chronic inflammation, increase oxidative stress, and genomic alteration. Therapeutic options of HCC have been primarily local and/or regional including transplantation, resection, and radial frequency ablation, chemoembolization or radio-embolization. For unresectable or metastatic disease, the options are limited. Conventional chemotherapeutic options have been noted to have limited benefit. Sorafenib has been the one and only systemic therapy which has demonstrated modest overall survival benefit. This has led to more extensive research with focus on targeted therapy. Numerous pre-clinical and early phase clinical studies have been noted but failed to show efficacy in later phase clinical trials. In an effort to identify new potential therapeutic options, new understanding of underlying pathways to hepatocarcinogenesis should be one of the main focuses. This leads to development of more molecularly targeted agents to specific pathways, and immunotherapy. This article provides a review of major studies of molecular targeted agents which attempts to target these specific pathways in HCC.

show abstract

A phase II study of sunitinib in advanced hepatocellular carcinoma

Cited by 21 publications

References 29 publications

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges

Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges

Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy

Contact Info

Product

Resources

About